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Abstract
Rationale Pupillometry can be used to characterize auto-
nomic drug effects.
Objective This study was conducted to determine the auto-
nomic effects of 3,4-methylenedioxymethamphetamine
(MDMA, ecstasy), administered alone and after pretreat-
ment with reboxetine, duloxetine, clonidine, carvedilol,
and doxazosin, on pupillary function.
Methods Infrared pupillometry was performed in five
placebo-controlled randomized studies. Each study included
16 healthy subjects (eight men, eight women) who received
placebo–MDMA (125 mg), placebo–placebo, pretreatment–
placebo, or pretreatment–MDMA using a crossover design.
Results MDMA produced mydriasis, prolonged the latency,
reduced the response to light, and shortened the recovery
time. The impaired reflex response was associated with
subjective, cardiostimulant, and hyperthermic drug effects
and returned to normal within 6 h after MDMA administra-
tion when plasma MDMA levels were still high. Mydriasis
was associated with changes in plasma MDMA concentra-
tion over time and longer-lasting. Both reboxetine and
duloxetine interacted with the effects of MDMA on pupil-
lary function. Clonidine did not significantly reduce the
mydriatic effects of MDMA, although it produced miosis
when administered alone. Carvedilol and doxazosin did not
alter the effects of MDMA on pupillary function.
Conclusions The MDMA-induced prolongation of the la-
tency to and reduction of light-induced miosis indicate
indirect central parasympathetic inhibition, and the faster
recovery time reflects an increased sympathomimetic action.
Both norepinephrine and serotonin mediate the effects of
MDMA on pupillary function. Although mydriasis is lasting
and mirrors the plasma concentration–time curve of
MDMA, the impairment in the reaction to light is associated
with the subjective and other autonomic effects of MDMA
and exhibits acute tolerance.
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Introduction
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)
induces the transporter-mediated release of serotonin and
norepinephrine (Liechti and Vollenweider 2001; Rothman
et al. 2001; Verrico et al. 2007) and produces cardiostimu-
lant and psychostimulant effects in humans (Hysek et al.
2011). The autonomic sympathomimetic effects of MDMA
in humans include increases in blood pressure, heart rate,
body temperature, and pupil diameter (Farre et al. 2004,
2007; Hysek et al. 2012c; Kolbrich et al. 2008; Liechti et
al. 2001; Mas et al. 1999). Pupil size and the response to a
flashlight stimulus are typically assessed in the evaluation of
intoxicated patients. Mydriasis is a clinical hallmark of
sympathomimetic toxicity in cases of ecstasy or cocaine
use. Laboratory studies have also shown an increase in pupil
diameter after MDMA administration (Farre et al. 2004,
2007; Kolbrich et al. 2008; Mas et al. 1999). However,
whether MDMA alters the pupillary light reflex response
and how pupillary changes are linked to MDMA exposure
and other pharmacodynamic effects of the drug are unknown.
Additionally, the pharmacological mechanism by which
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MDMA produces mydriasis and the potential changes in
pupillary function are unclear. Mydriasis and alterations in
the pupillary light reflex may result from increased sympa-
thetic activity, the release of norepinephrine, and α1-adrener-
gic receptor stimulation directly in the iris or from a decrease
in parasympathetic activity (Loewenfeld 1999). At the level of
the iris, the latency to the light reflex and miotic response to
light are thought to reflect parasympathetic activation (Heller
et al. 1990; Loewenfeld 1999), whereas redilation is consid-
ered to mainly reflect sympathetic activation (Loewenfeld
1999; Morley et al. 1991). Notably, the parasympathetic input
to the pupil may also be inhibited centrally via α2-adrenergic
receptors in the Edinger–Westphal nucleus by an increase in
sympathetic activity (Phillips et al. 2000a; Siepmann et al.
2007; Szabadi and Bradshaw 1996). Furthermore, the seroto-
nin system has been shown to indirectly influence pupillary
function, possibly by enhancing sympathetic activity (Prow et
al. 1996). Therefore, the MDMA-induced release of norepi-
nephrine in the periphery may stimulate α1-adrenergic recep-
tors in the iris or inhibit parasympathetic activity via central
α2-adrenergic receptors in the Edinger–Westphal nucleus. The
adrenergic mechanismsmay be further enhanced by the potent
MDMA-induced release of serotonin. To explore the mecha-
nism of action of MDMA on pupillary function, we investi-
gated the effects of five pretreatments on the response to
MDMA. We used the norepinephrine transporter inhibitor
reboxetine to block the transporter-mediated, MDMA-
induced release of norepinephrine (Hysek et al. 2011; i.e.,
the indirect sympathomimetic effect of MDMA). The seroto-
nin and norepinephrine transporter inhibitor duloxetine was
similarly used to block the MDMA-induced, transporter-
mediated release of both serotonin and norepinephrine
(Simmler et al. 2011). The α2-adrenergic agonist clonidine
was used as a sympathicolytic to inhibit the transporter-
independent vesicular release of norepinephrine (Hysek et
al. 2012a). Carvedilol and doxazosin were used to block
postsynaptic α1β1–3- and α1-adrenergic receptors, respective-
ly (Hysek et al. 2012c; i.e., to directly antagonize the effects of
norepinephrine in the iris, on the cardiovascular system, and
on body temperature). The series of studies included addition-
al outcome measures presented elsewhere (Hysek et al. 2011,
2012a, b, d; Simmler et al. 2011).
Material and methods
Study design
This was a pooled analysis of five double-blind, double-
dummy, placebo-controlled, randomized, crossover studies
(Hysek et al. 2011, 2012a, b, d; Simmler et al. 2011). The
primary aim of the pooled analysis was to assess the effects
of MDMA on pupil size and pupillary light reflex compared
with placebo in all 80 subjects and to explore associations with
the pharmacokinetics of MDMA and other pharmacodynamic
measures. All of the subjects included in the five studies
received MDMA, placebo, one of five different pretreatments
prior to MDMA, or the pretreatment alone (Fig. 1). Thus, the
four experiential conditions for all of the subjects were place-
bo–placebo, pretreatment–placebo, placebo–MDMA, and pre-
treatment–MDMA in a balanced order. Each of the five studies
included 16 subjects (eight male, eight female). The pretreat-
ments used in the five studies were reboxetine, duloxetine,
clonidine, carvedilol, and doxazosin. The random allocation
sequencewas developed by a clinical pharmacist and concealed
from all of the individuals involved in the study management.
The washout periods between sessions were ≥10 days. The
studies were conducted in accordance with the Declaration of
Helsinki and International Conference on Harmonization
Guidelines on Good Clinical Practice and approved by the
Ethics Committee of the Canton of Basel, Switzerland. The
use of MDMA in healthy subjects was authorized by the Swiss
Federal Office of Public Health, Bern, Switzerland. The studies
were registered at ClinicalTrials.gov (NCT00886886,
NCT00990067, NCT01136278, NCT01270672, and
NCT01386177).
Participants
Eighty healthy subjects (40 men and 40 women) aged 18
to 44 years (mean ± SD, 25±5 years) were recruited on
the university campus. The exclusion criteria included the
following: (1) age <18 or >45 years, (2) pregnancy
determined by a urine test before each test session, (3)
body mass index <18.5 or >25 kg/m2, (4) personal or
family (first-degree relative) history of psychiatric disor-
der [determined by the structured clinical interview for
axis I and axis II disorders according to the Diagnostic
and Statistical Manual of Mental Disorders, 4th edition
(Wittchen et al. 1997), supplemented by the SCL-90-R
Symptom Checklist (Derogatis et al. 1976; Schmitz et al.
2000)], (5) the regular use of medications, (6) chronic or
acute physical illness assessed by physical examination,
electrocardiogram, standard hematology, and chemical
blood analyses, (7) smoking more than 10 cigarettes per
day, (8) a lifetime history of using illicit drugs more than
five times, with the exception of cannabis, (9) illicit drug
use within the last 2 months, and (10) illicit drug use
during the study determined by urine tests conducted
before the test sessions using TRIAGE 8 (Biosite, San
Diego, CA, USA). The subjects were asked to abstain
from excessive alcohol consumption between test ses-
sions and limit alcohol use to one drink on the day
before each test session. Eight of the 80 subjects had
previously tried ecstasy (one to two times). Female sub-
jects were investigated during the follicular phase (day
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2–14) of their menstrual cycle to account for the poten-
tial confounding effects of sex hormones and cyclic
changes in the reactivity to amphetamines (White et al.
2002). All of the subjects provided their written informed
consent before participating in the study, and they were
paid for their participation.
Measures
Pupillometry
Pupillometry was performed 1 h before and 0, 0.33, 0.66, 1,
1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo
administration. Pupil function was measured under stan-
dardized dark–light conditions of 5.7±0.8 lx assessed by a
Voltcraft MS-1300 lux meter (Voltcraft, Hirschau, Germany)
following a dark adaption time of 1 min. Pupillometry was
performed using a handheld PRL-200 infrared pupillometer
(NeurOptics, Irvine, CA, USA; Taylor et al. 2003). The
subjects were instructed to focus on a black dot on a white
wall at a distance of 4 m. After a 10-s focusing period,
measurements were taken for 5 s. During this time frame,
the following parameters were assessed: dark-adapted pupil
diameter (MAX), minimal pupil diameter after a light
stimulus (MIN), and latency to the pupillary light reflex
(Fig. 2). The constriction amplitude was calculated as
MAX−MIN. The time taken by the pupil to recover 75 %
of the initial resting pupil size after it reached constriction
Assessed for eligibility (n=92)
Screening
Excluded (n=12)
•Refused to participate (n=3)
•Medical reason (n=8)
•noncompliance (n=1)
Randomized (n=80) assignment of order of 
4 drug conditions for each subject
Placebo-Placebo 
(n=80)
Placebo-MDMA
(n=80)
Reboxetine-Placebo
(n=16)
Reboxetine-MDMA
(n=16)
All participants completed the study (n=80) Drop outs (n=0)
Data analyzed (n=80)
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(n=16)
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Fig. 2 Schematic drawing of the light reflex response.MAX represents
the dark-adapted resting pupil size before the light stimulus. Latency
represents the time of the onset of constriction. MIN represents the
minimal pupil size after the light stimulus. The constriction amplitude
was calculated as MAX−MIN. The 75 % recovery time is the time to
recover 75 % of the initial resting pupil size after reaching MIN
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was also assessed. The dynamic pupil measurements
were triggered by a light impulse of 180 μW intensity
and duration of 167 ms. Measurements were performed
on both eyes, and the average values were used for
further analyses.
Subjective drug effect
Subjective drug effects were assessed using visual analog
scales (VAS) reported in detail elsewhere (Hysek et al. 2011,
2012a). In the present report, we included only the VAS
rating of “any subjective drug effects,” measured using a
1000mm horizontal line marked “not at all” on the left and
“extremely” on the right. The VAS was repeatedly admin-
istered 1 h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, and
6 h after MDMA or placebo administration. The scale is
very sensitive to the overall psychotropic effects of MDMA
(Farre et al. 2007; Hysek et al. 2011). The comprehensive
assessments of different aspects of the psychotropic re-
sponse to MDMA have been presented in the reports of
the individual studies (Hysek et al. 2011, 2012a, b, d).
Blood pressure, heart rate, and body temperature
Blood pressure and heart rate were assessed repeatedly
before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h
after MDMA or placebo administration using an
OMRON M7 monitor (Omron Healthcare Europe,
Hoofddorp, The Netherlands) in the dominant arm and
after a resting time of 5 min. Measures were taken
twice per time point with an interval of 1 min, and
the average was used for analysis. Mean arterial pres-
sure (MAP) was calculated from diastolic and systolic
blood pressure using the formula MAP 0 diastolic blood
pressure + (systolic blood pressure−diastolic blood pres-
sure)/3. Core (tympanic) temperature was assessed using
a GENIUS 2 ear thermometer (Tyco Healthcare Group,
Watertown, NY, USA).
Pharmacokinetics of MDMA
Blood samples were collected before and 0, 0.33, 0.66, 1,
1.5, 2, 2.5, 3, 4, and 6 h after MDMA or placebo adminis-
tration, and plasma MDMA levels were determined as pre-
viously described (Hysek et al. 2012a). The data for the
plasma concentrations of MDMAwere analyzed using non-
compartmental methods. Maximal plasma concentration and
the time to maximal plasma concentration were obtained
directly from the concentration–time curves of the observed
values. Plasma concentrations were only determined up to
6 h after MDMA administration because the aim of the
study was to assess plasma exposure only during the time
of the pharmacodynamic effects of MDMA.
Drugs
(±)-MDMA hydrochloride (Lipomed AG, Arlesheim, Swit-
zerland) was prepared as gelatin capsules (100 and 25 mg).
Identical placebo (mannitol) capsules were prepared. MDMA
was administered in a single absolute oral dose of 125 mg.
This dose of MDMA corresponds to a typical recreational
dose or the dose of MDMA used as an adjunct to psychother-
apy (Mithoefer et al. 2010). In the reboxetine–MDMA study,
reboxetine (Edronax; 8 mg; Pfizer, Zurich, Switzerland) or
identical placebo was administered at 8:00 p.m. on the day
before the test session and again at 7:00 a.m. on the test day.
MDMA or placebo was administered at 8:00 a.m., 1 and 12 h
after reboxetine. In the duloxetine–MDMA study, duloxetine
(Cymbalta; 120 mg; Eli Lilly, Vernier, Switzerland) or identi-
cal placebo was administered at 8:00 p.m. on the day before
the test session and again at 8:00 a.m. on the test day. MDMA
or placebo was administered at 12:00 p.m., 4 and 16 h after
duloxetine. Reboxetine and duloxetine were administered
twice at high doses to obtain peak plasma concentrations of
(mean ± SD) 372±34 and 107±10 ng/ml, respectively, similar
to the concentrations reached with chronic daily administra-
tion of 4 and 60 mg of the drugs, respectively (Hysek et al.
2011; Simmler et al. 2011), and as previously used to manip-
ulate noradrenergic function in healthy subjects (Roelands et
al. 2008). Compliance with the first administration of rebox-
etine and duloxetine on the evening prior to the test day was
confirmed analytically in plasma (Hysek et al. 2011, 2012d).
In the clonidine–MDMA study, clonidine (Catapresan;
150 μg; Boehringer Ingelheim, Basel, Switzerland) or identi-
cal placebo was administered at 8:00 a.m., 1 h before MDMA
or placebo (9:00 a.m.; Hysek et al. 2012a). Clonidine has
previously been shown to produce sympatholytic effects at
this dose in healthy subjects (Anavekar et al. 1982; Bitsios et
al. 1996; Nieuwenhuis et al. 2007) and was expected to
produce peak plasma concentrations in the range of 0.6–
0.7 ng/ml (Anavekar et al. 1982; Keranen et al. 1978). In the
carvedilol–MDMA study, carvedilol (Dilatrend; 50 mg;
Roche, Basel, Switzerland) or identical placebo was adminis-
tered at 8:00 a.m., 1 h before MDMA or placebo (9:00 a.m.;
Hysek et al. 2012c). The same dose of carvedilol has previ-
ously been shown to attenuate the smoked cocaine-induced
increases in heart rate and blood pressure in humans (Sofuoglu
et al. 2000) and was expected to produce peak plasma con-
centrations in the range of 120–180 mg/ml (Henderson et al.
2006; Morgan 1994). At this dose, carvedilol is expected to
inhibit both α1- and β-adrenergic receptors (Sofuoglu et al.
2000; Tham et al. 1995), with fivefold to tenfold higher
activity at β receptors (Tomlinson et al. 1988, 1992). In the
doxazosin–MDMA study, continued-release doxazosin (Car-
dura; 4 mg; Pfizer, Zurich, Switzerland) or identical placebo
was used. A first dose of 4 mg of doxazosin was administered
3 days before MDMA or placebo (−64 h) at 5:00 p.m., a
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second dose of 8 mg was administered 2 days before MDMA
or placebo (−40 h) at 5:00 p.m., and a third dose of 8 mg was
administered the day before MDMA or placebo administra-
tion (−16 h) at 5:00 p.m. The subjects were reminded by a
phone call or phone text message to ingest the capsules, and
medication containers were checked to confirm that the first
two doses of doxazosin were administered. The last adminis-
tration was supervised by study personnel at the research
facility. This administration schedule accounted for the long
tmax of 8–10 h of the continuous-release formulation of dox-
azosin and reduced the risk of hypotension (Chung et al.
1999). Based on similar dosing regimes in healthy subjects
(Chung et al. 1999; Shirai et al. 2010), the mean estimated
peak plasma concentration of doxazosin was 30±5 ng/ml,
similar to the concentration with steady-state dosing of 4 mg
(Chung et al. 1999). The pretreatment times for the adminis-
tration of the five pretreatments resulted in maximal plasma
concentrations of the pretreatments at the time of or shortly
before the maximal effect of MDMA, based on our analytical
results (Hysek et al. 2011, 2012a, c, d) or published data
(Anavekar et al. 1982; Chung et al. 1999; Henderson et al.
2006; Keranen et al. 1978; Morgan 1994; Shirai et al. 2010).
Oral drug administration on the test days was supervised by
study personnel.
Statistical analyses
Maximal effect values (Emax), minimal effect values
(Emin; only for clonidine), and areas under the effect–
time curves were determined with repeated measures.
Values from the five studies were separately compared
using two-way factorial general linear models repeated-
measures analysis of variance (ANOVA), with the factors
MDMA (MDMA vs. placebo) and pretreatment (pretreat-
ment vs. placebo), using STATISTICA 6.0 software (Stat-
Soft, Tulsa, OK, USA). Additionally, MDMA and
placebo values from all of the studies were pooled and
analyzed with MDMA as a single within-subjects factor.
Tukey post hoc comparisons were performed based on
significant main effects or interactions in the ANOVA.
Analyses of the area under the effect–time curve data
yielded identical results to those of the maximal values
and are, therefore, not shown. Associations between the
pharmacodynamic changes and plasma concentration of
MDMA were analyzed using Spearman’s rank correla-
tions. This first correlation analysis assessed the associa-
tions of the parameters between subjects (n080) for each
time point. The mean pharmacodynamic changes after
MDMA administration for each time point were then
plotted against the respective mean plasma concentrations
of MDMA and graphed as hysteresis curves. Correlations
between the pharmacodynamic–pharmacokinetic data
pairs over time (n09 time points) were then analyzed
using Spearman’s rank correlation. Associations between
pupillary function parameters and cardiovascular or sub-
jective effects were similarly analyzed (n010 time
points). This second correlation analysis assessed the
associations of mean parameter changes from baseline
over time within the 16 subjects (n09 or 10). The
criterion for significance was p<0.05.
Results
Parameters of pupillary function (placebo condition)
Pupillary function parameters were measured 10 times in 80
subjects after placebo administration. Mean ± SEM values
were as follows: pupil size06.23±0.09 mm, pupil size after
light04.34±0.08 mm, constriction amplitude01.90±
0.01 mm, and recovery time02.46±0.06 s. Maximal values
are shown in Table 1. The diameter of the light-stimulated
pupil correlated with the resting pupil size prior to the light
stimulus (Rs00.94, p<0.001, n080).
Effects of MDMA on pupillary function
MDMA increased pupil size both at rest and after the
light stimulus and lowered the constriction amplitude
compared with placebo (Fig. 3; Table 1). The effect of
MDMA on pupil size peaked (mean ± SEM) 2.3±0.2 h
after drug administration at the time of the maximal
plasma concentration of MDMA and remained high over
6 h in parallel with plasma levels that also remained high
over 6 h (Fig. 3a). The effect of MDMA on the con-
striction amplitude was maximal 1.7±0.1 h after drug
administration and decreased to baseline levels over 6 h
(Fig. 3b) despite high plasma levels of MDMA. MDMA
also prolonged the latency to the pupillary light reflex
and shortened the recovery time of the pupillary light
reflex response (Table 1).
Subjective effects of MDMA
MDMA produced significant subjective drug effects com-
pared with placebo (Table 1). The peak effect was
reached 1.5±0.1 h after MDMA administration (Fig. 3c).
The subjective effects of MDMA completely reverted to
baseline within 6 h, although the plasma levels of
MDMA remained high (Fig. 3c). The effects of the pre-
treatments on the subjective response to MDMA are
reported in detail elsewhere (Hysek et al. 2011, 2012a,
b, d). Briefly, reboxetine and duloxetine reduced the
subjective effects of MDMA, whereas the other pretreat-
ments overall had no effect on the subjective response to
MDMA (Hysek et al. 2012c).
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Table 1 Effects of MDMA
n080 (values from all five stud-
ies were pooled)
Placebo
(mean ± SEM)
MDMA
(mean ± SEM)
F1,79 p value
Pupil size (mm) Emax 6.60±0.09 7.58±0.07 288.1 <0.001
Pupil size after light (mm) Emax 4.76±0.09 6.86±0.09 646.9 <0.001
Constriction amplitude (mm) Emax 1.76±0.06 0.81±0.12 328.0 <0.001
Latency (s) Emax 0.25±0.00 0.33±0.02 16.2 <0.001
Recovery time (s) Emax 1.74±0.06 1.17±0.07 57.3 <0.001
Subjective drug effect (percent maximum) Emax 3.5±1.7 81.0±2.8 901.2 <0.001
Mean arterial pressure (mmHg) Emax 95.0±1.0 114.5±1.2 339.7 <0.001
Heart rate (bpm) Emax 76.0±1.2 96.2±1.9 138.1 <0.001
Body temperature (°C) Emax 37.3±0.1 37.6±0.1 26.2 <0.001
Placebo MDMA MDMA plasma levels
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Fig. 3 Acute effects of MDMA on pupil function. Values are
expressed as the mean ± SEM of 80 subjects. MDMA increased resting
pupil size compared with placebo (a). The mydriatic effect of MDMA
remained high in parallel with the plasma concentration of MDMA.
MDMA reduced the pupil constriction amplitude compared with
placebo and this effect decreased more rapidly than the plasma con-
centration of MDMA (b). The subjective (c), cardiovascular (d, e), and
thermogenic (f) effects of MDMA also disappeared within 6 h when
the plasma concentrations of MDMA were still high
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Effects of MDMA on blood pressure, heart rate, and body
temperature
MDMA significantly increased blood pressure, heart rate,
and body temperature compared with placebo (Table 1;
Fig. 3d–f). Similar to the subjective effects, MDMA-
induced increases in blood pressure and heart rate were
short-lasting.
Pharmacokinetics of MDMA
Plasma MDMA concentrations are shown in Fig. 3. The
peak plasma MDMA concentration was (mean ± SEM)
243±6 ng/ml. The time to maximum plasma concentra-
tion was 2.5±0.1 h.
Pharmacokinetic–pharmacodynamic and
pharmacodynamic–pharmacodynamic associations
The relationships between the concentration of MDMA and
its pharmacodynamic effects are shown in Fig. 4a–c. The
average group pupil size was correlated with the average
plasma levels of MDMA over time (Rs00.77, p<0.01, n09),
with moderate clockwise hysteresis (Fig. 4a). In contrast, the
MDMA-induced reduction in constriction amplitude was not
significantly associated with the plasma concentrations of
MDMA (Rs00.43, p00.24, n09), attributable to pronounced
clockwise hysteresis (Fig. 4b). There was a similar marked
hysteresis in the relationship between the concentration of
MDMA and the subjective drug effects (Fig. 4c) and no
correlation between the two (Rs00.48, p00.17, n09). The
association between the average subjective effect and pupil
size over time was relatively strong (Rs00.77, p<0.01, n010),
but hysteresis was observed in the relationship between sub-
jective effects and pupil size over time (Fig. 4d), indicating
that the subjective effects decreased more rapidly than the
mydriasis associated with MDMA. In contrast, little or no
hysteresis was observed in the plot of the relationship of
subjective effects with constriction amplitude (Fig. 4e), indi-
cating a closer association and more congruent subjective and
dynamic pupillary effects of MDMA, also demonstrated by a
very strong correlation between the means of these two effects
over time (Rs00.96, p<0.001, n010; Fig. 4e). There were
similar strong associations between MDMA-induced reduc-
tions in constriction amplitude and changes in MAP, heart
rate, and body temperature (Rs00.98, 0.92, 0.87; all p<0.001,
n010). Between-subjects correlations further showed that
subjective effects were strongly correlated with reductions in
the light reflex but not with pupil size (Table 2). MDMA-
induced increases in blood pressure and heart rate did not
0 50 100 150 200 250
6.2
6.4
6.6
6.8
7.0
7.2
7.4
7.6
0.3 h
0.6 h
1 h
1.5 h 2 h 2.5 h
3 h
4 h
6 h
MDMA (ng/ml)
Pu
pi
l s
ize
 (m
m)
0 50 100 150 200 250
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
0.3 h
0.6 h
1 h
1.5 h2 h
2.5 h
3 h
4 h
6 h
MDMA (ng/ml)
Co
ns
tri
ct
io
n 
(m
m)
0 50 100 150 200 250
0
20
40
60
80
0.3 h
0.6 h
1 h
1.5 h
2 h
2.5 h
3 h
4 h
6 h
MDMA (ng/ml)
Su
bje
cti
ve
 dr
ug
 ef
fec
t (%
)
6.2 6.4 6.6 6.8 7.0 7.2 7.4
0
20
40
60
80
0.3 h
0.6 h
1 h
1.5 h
2 h
2.5 h
3 h
4 h
6 h
5 h
Pupil size (mm)
Su
bje
cti
ve
 dr
ug
 ef
fec
t (%
)
0.51.01.52.0
0
20
40
60
80
0.3 h
0.6 h
1 h 1.5 h
2 h
2.5 h
3 h
4 h
6 h
5 h
Constriction (mm)
Su
bje
cti
ve
 dr
ug
 ef
fec
t (%
)
CBA
ED
Fig. 4 Pharmacokinetic–pharmacodynamic relationship. MDMA
effects plotted against the plasma concentrations of MDMA (a–c).
The values are expressed as the means of 80 subjects, with SEM
omitted for clarity. The times of pupillometry and blood sampling are
noted next to each point in minutes or hours after MDMA administra-
tion. While pupil size (a) remained high, constriction amplitude (b) and
subjective effect (c) returned to baseline within 6 h when MDMA
concentrations remained high. This clockwise hysteresis was moderate
for the mydriatic effect of MDMA, reflecting well the plasma concen-
tration of MDMA (a), but pronounced for the impairment in the
pupillary reflex response (b) and subjective effect of MDMA (c). The
subjective effect of MDMA returned to baseline faster than the myd-
riatic response to MDMA (d). In contrast, the time course of the
subjective effect of MDMA was more congruent with the time course
of the MDMA-induced impairment in constriction amplitude (e)
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correlate with the plasma concentrations ofMDMAover time,
consistent with the reduced effect over time despite high
plasma concentrations of MDMA (Fig. 3d, e).
The findings from the between-subjects analyses of the
correlations between the plasma levels of MDMA and phar-
macodynamic effects of MDMA for each time point (n080)
are shown in Table 3. The MDMA-induced reductions in the
constriction amplitude, the pupil size after light, the increase in
MAP, and the subjective effects were significantly and strongly
associated with the plasma levels of MDMA (Table 3).Weaker
correlations were also found between plasma levels of MDMA
and the pupil diameter, latency, or heart rate (Table 3). How-
ever, these associations were only observed at the beginning of
the MDMA effect. Recovery time and body temperature after
MDMA administration were not or only weakly and inconsis-
tently associated with plasma MDMA levels (Table 3).
The MDMA-induced reduction in pupil constriction am-
plitude was significantly greater in subjects with greater
MDMA-induced increases in MAP (Rs00.56, p<0.001,
n080) or more pronounced increases in heart rate (Rs00.30,
p<0.01, n080) as measured 1 h after MDMA administration.
In contrast, MDMA-induced changes in the pupil size were
not or only poorly associated with other autonomic changes
across subjects.
Pupillary effects of reboxetine, duloxetine, clonidine,
carvedilol, and doxazosin alone and on the pupillary
response to MDMA
The peak effects of the pretreatments are shown in Table 4.
The drug effects on pupil size over time for all five studies
are shown in Fig. 5. Both reboxetine and duloxetine in-
creased resting pupil size and pupil size after the light
stimulus. Duloxetine also lowered the constriction ampli-
tude (Table 4). The effect of the two monoamine uptake
inhibitors on the static pupil diameter was similar in mag-
nitude to the effect of MDMA (Table 4; Fig. 5a, b). In
contrast, the effect of MDMA on the constriction amplitude
was more pronounced. When duloxetine was administered
together with MDMA, the drug effects on all static and
dynamic parameters were nonadditive and showed negative
synergism, reflected by a significant pretreatment × MDMA
interaction in the factorial ANOVA. Thus, duloxetine pre-
vented the effect of MDMA on pupil function, reflected by
the absence of a mydriatic effect of MDMA compared with
baseline in the duloxetine–MDMA condition and compared
with the duloxetine–placebo condition (Fig. 5b). Duloxetine
also prevented the MDMA-induced impairment in the pu-
pillary light reflex, although it had a similar effect when
Table 2 Correlations between MDMA-induced changes in pupillary function and subjective drug effects
t00 t020 min t040 min t01 h t01.5 h t02 h t02.5 h t03 h t04 h t06 h
Pupil size (mm) NS NS 0.31 0.27 NS NS NS NS NS NS
Pupil size after light (mm) NS NS 0.62 0.51 0.42 0.26 0.27 NS NS NS
Constriction amplitude (mm) NS NS −0.74 −0.61 −0.41 −0.28 −0.28 −0.28 −0.23 NS
Latency (s) NS NS 0.46 0.29 NS NS NS NS NS NS
Recovery time (s) NS NS −0.42 −0.31 −0.32 −0.22 −0.38 −0.23 −0.28 −0.32
Values are Spearman correlation coefficients for significant correlations (p<0.05; p<0.001 in italics); n080
NS not significant
Table 3 Correlations between the effects of MDMA and plasma concentrations of MDMA
t00 t020 min t040 min t01 h t01.5 h t02 h t02.5 h t03 h t04 h t06 h
Pupil size (mm) NS 0.46 0.45 0.35 0.27 NS NS NS NS NS
Pupil size after light (mm) NS 0.50 0.64 0.57 0.54 0.53 0.49 0.47 0.34 NS
Constriction amplitude (mm) NS −0.28 −0.40 −0.55 −0.53 −0.60 −0.55 −0.65 −0.48 −0.28
Latency (s) NS 0.23 0.46 0.33 0.35 NS 0.25 0.25 NS 0.25
Recovery time (s) NS NS −0.32 NS −0.26 NS −0.37 −0.26 −0.26 NS
Subjective drug effect NS NS 0.68 0.56 0.37 0.31 0.44 0.34 0.46 0.31
Mean arterial pressure (mmHg) NS 0.22 0.69 0.60 0.47 0.35 0.33 0.29 0.39 NS
Heart rate (bpm) NS NS 0.61 0.47 0.46 0.32 NS NS NS NS
Body temperature (°C) NS −0.24 NS NS NS NS NS NS NS NS
Values are Spearman correlation coefficients for significant correlations (p<0.05; p<0.001 in italics) between MDMA-induced pharmacodynamic
changes and plasma levels of MDMA; n080
NS not significant
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administered alone compared with placebo. The effects
of reboxetine and MDMA on pupil size were also
nonadditive (Table 4; Fig. 5b). However, resting pupil
size and pupil size after the light stimulus were signif-
icantly larger after reboxetine plus MDMA compared
with MDMA alone. Reboxetine also failed to prevent
the effect of MDMA on the pupillary light reflex. In the
present study, reboxetine also reduced the cardiostimu-
lant and psychostimulant effects of MDMA (Hysek et
al. 2011), and duloxetine nearly completely prevented
the cardiovascular, psychotropic, and neuroendocrine
effects of MDMA as reported elsewhere (Hysek et al.
2012b, d; Simmler et al. 2011). Clonidine reduced rest-
ing pupil size and size after the light stimulus (Table 4;
Fig. 5c). This effect of clonidine was antagonistic and
overall additive with the effect of MDMA (Fig. 5c).
Specifically, clonidine did not significantly reduce the
effects of MDMA on any parameter of pupillary func-
tion, although it had significant effects alone and re-
duced the cardiovascular response to MDMA (Hysek et
al. 2012a). Clonidine did not significantly reduce the
mydriatic effects of MDMA, although it produced sig-
nificant miosis. Clonidine also had no effects on the
psychotropic response to MDMA as previously reported
(Hysek et al. 2012a). Carvedilol did not alter the effects
of MDMA on pupillary function. In contrast, carvedilol
decreased the cardiostimulant and thermogenic effects of
MDMA in the same subjects as reported elsewhere
(Hysek et al. 2012c). Carvedilol alone decreased pupil
size, reflected by a significant main effect of pretreat-
ment in the ANOVA, but the reduction in pupil size
after carvedilol–placebo treatment compared with the
placebo–placebo condition (Fig. 5d) was not significant
in the post hoc test. Doxazosin alone had no effect on
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Fig. 5 Drug effects on pupil
size over time.MDMA increased
pupil size compared with
placebo (a–e). The pretreatment
with reboxetine increased pupil
size to a similar extent as
MDMA alone (a). The effect of
MDMA on pupil diameter after
reboxetine pretreatment
compared with reboxetine was
significantly smaller than the
effect of MDMA compared with
placebo (a). Duloxetine
increased pupil size similar to
reboxetine and MDMA (b).
Duloxetine pretreatment
prevented the further increase in
pupil size induced by MDMA
administration (b). Clonidine
significantly reduced pupil
diameter (c). The effects of
clonidine and MDMA on pupil
size were additive (c). Carvedilol
nonsignificantly decreased pupil
size (d). Similar to the effects of
clonidine and MDMA, the
effects of carvedilol and MDMA
on pupil size were additive (d).
Doxazosin alone had no effect on
pupil size compared with
placebo, but it tended to
nonsignificantly attenuate the
mydriatic effect of MDMA (e).
The data are expressed as the
mean ± SEM values in 16
subjects per study
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pupil size compared with placebo but slightly and non-
significantly reduced the MDMA-induced increase in
pupil size (Fig. 5e).
Discussion
In the present study, we showed that MDMA impaired the
pupillary reflex response to light, including inducing a lon-
ger latency, reducing the constriction amplitude, and reduc-
ing the recovery time. MDMA produced mydriasis as
previously documented using nonautomated techniques
(Farre et al. 2004, 2007; Kolbrich et al. 2008; Mas et al.
1999). MDMA also increased blood pressure, heart rate, and
body temperature and produced positive mood effects as
described in more detail elsewhere (Hysek et al. 2011,
2012a, b, d).
The analyses of the effects of MDMA over time showed
a very strong correlation between the MDMA-induced re-
duction in constriction amplitude and other autonomic or
subjective effects of the drug. The MDMA-induced reduc-
tion in the pupillary light reflex normalized over 6 h, similar
to the cardiostimulant and subjective drug effects that also
largely disappeared over 6 h, although the plasma levels of
MDMA remained high. Thus, the reduced reactivity of the
pupil to light is relatively short-lasting and subject to acute
pharmacological tolerance, similar to the subjective and
cardiostimulant effects of MDMA.
Clinical examination of pupil function in cases of drug
intoxication typically includes both an estimation of static
pupil size and an assessment of the reactivity to a flashlight
stimulus. With regard to MDMA intoxication, our findings
suggest that the impaired reactivity to light indicates
MDMA exposure within the past 1–4 h and is a marker
for the acute subjective and autonomic effects of the drug. In
contrast, mydriasis lasts at least 6–10 h (Farre et al. 2007;
Mas et al. 1999), correlates best with the plasma MDMA
concentration changes over time, and shows only moderate
pharmacological tolerance. The mydriatic responses to two
successive doses of MDMA separated by 24 h were similar,
although the peak concentration after the second dose of
MDMA increased by 29 %, indicating some degree of
tolerance (Farre et al. 2004). Although the mean group
changes in pupil size over time reflected the concentra-
tion–time curve of MDMA, pupil size did not correlate well
with the plasma concentrations of MDMA across subjects at
various time points in our study or with MDMA plasma
levels 1.25 h after drug administration in a previous study
(Kolbrich et al. 2008). This is not surprising because the
effects of MDMA on pupil size were maximal at single
doses of 75 mg and did not further increase at 125 mg
(Mas et al. 1999). Thus, the lack of an association is likely
attributable to a ceiling effect of the plasma MDMA
concentration–effect curve. In contrast, dynamic impair-
ments of the pupil light reflex response were significantly
associated with plasma MDMA levels or the cardiostimulant
effects of MDMA across subjects. Evaluating the dynamic
pupillary response to light may, therefore, be a better esti-
mation of the time and amount of exposure to MDMA than
static pupil size.
Both sympathetic and parasympathetic innervations con-
tribute to the regulation of pupil size and the reflex response
(Loewenfeld 1999). At the level of the iris, the latency to
and amplitude of the reflex response are mainly determined
by parasympathetic activity (Heller et al. 1990), whereas
redilation is controlled by sympathetic inputs (Loewenfeld
1999; Morley et al. 1991). Additionally, parasympathetic
function is under tonic noradrenergic inhibition centrally at
the level of the Edinger–Westphal nucleus where the sym-
pathetic stimulation of α2-adrenergic receptors may lower
parasympathetic output, resulting in “pseudoanticholiner-
gic” mydriasis (Phillips et al. 2000a; Siepmann et al. 2007;
Szabadi and Bradshaw 1996). Furthermore, the serotonin
system is implicated in pupillary function, possibly via 5-
HT1A-mediated stimulation of the release of norepinephrine
and consequent activation of α2-adrenergic receptors (Prow
et al. 1996). MDMA mainly releases serotonin and norepi-
nephrine (Liechti and Vollenweider 2001; Rothman et al.
2001; Verrico et al. 2007). Because MDMA affected both
the parasympathetic and sympathetic aspects of the pupil-
lary reflex response, all of the aforementioned mechanisms
may be involved in the effects of MDMA on pupillary
function.
The norepinephrine transporter inhibitor reboxetine sig-
nificantly increased pupil diameter at rest and after light,
consistent with previous studies (Theofilopoulos et al.
1995). Reboxetine did not reduce the mydriatic response
to MDMA, but the effects of the two drugs on pupil size
were subadditive, indicating that MDMA produces part of
its effects on pupil size through the transporter-mediated
release of norepinephrine, which is inhibited by reboxetine
(Hysek et al. 2011). This finding is consistent with the
attenuation of the cardiostimulant and psychostimulant
effects of MDMA by reboxetine (Hysek et al. 2011) and
supports the view that norepinephrine is involved in the
stimulant effects of MDMA.
The α1-adrenergic receptor inhibitor doxazosin did not
affect pupillary function when administered alone but non-
significantly reduced the mydriatic response to MDMA.
Prazosin did not antagonize mydriasis induced by norepi-
nephrine or phenylephrine in anesthetized cats (Hey et al.
1988; Koss et al. 1988). The data suggest that α1-adrenergic
receptors in the iris may only minimally contribute to my-
driasis induced by systemically administered sympathomi-
metic drugs and that central parasympathetic inhibition may
be more relevant.
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The α1β-adrenergic receptor inhibitor carvedilol had no
significant effect on pupil size compared to placebo, consis-
tent with earlier work (Hirohashi et al. 1990) and the ab-
sence of effects of the β-adrenergic receptor blocker
propranolol on pupillary function (Koudas et al. 2009).
Carvedilol did not affect the mydriatic response to MDMA,
but it reduced other autonomic effects of MDMA, including
increases in blood pressure and body temperature (Hysek et
al. 2012c).
Clonidine decreased pupil diameter and enhanced the pu-
pillary reflex, consistent with its known sympatholytic effects
(Clifford et al. 1982; Morley et al. 1991; Phillips et al. 2000b,
c). Clonidine also lowered the plasma concentrations of nor-
epinephrine and blood pressure in the subjects of the present
study (Hysek et al. 2012a). The effect of clonidine on pupil
function is thought to involve the stimulation of α2-adrenergic
receptors on central noradrenergic neurons, leading to de-
creased sympathetic outflow to the iris. The enhancement of
the parasympathetic light reflex is consistent with clonidine-
induced disinhibition of the noradrenergic central control of
parasympathetic outflow (Phillips et al. 2000b). Despite its
significant sympathicolytic effects (Hysek et al. 2012a), clo-
nidine failed to significantly reduce the effects of MDMA on
pupillary function. Moreover, clonidine did not reduce the
MDMA-induced increase in norepinephrine or blood pressure
to the same extent as it reduced these parameters when admin-
istered alone (Hysek et al. 2012a). Thus, the sympatholytic
effects of clonidine and sympathomimetic effects of MDMA
were antagonistic in an additive manner, without evidence of
interactive effects of the two drugs. The findings indicate that
α2-adrenergic receptors and the vesicular release of norepi-
nephrine are not critically involved in the pharmacological
effects of MDMA.
The dual serotonin and norepinephrine transporter inhib-
itor duloxetine increased resting pupil diameter, prolonged
the latency to the light reflex, and reduced the reaction to
light. Identical effects on pupillary function have been
reported for the serotonin and norepinephrine transporter
inhibitor venlafaxine (Bitsios et al. 1999; Siepmann et al.
2007). Serotonin releasers, including fenfluramine (Kramer
et al. 1973), meta-chlorophenylpiperazine (Benjamin et al.
1997), and MDMA, and serotonin transporter inhibitors
(Nielsen et al. 2010; Noehr-Jensen et al. 2009; Schmitt et
al. 2002) also cause mydriasis. Citalopram and paroxetine
have also been shown to reduce the constriction amplitude
(Nielsen et al. 2010; Noehr-Jensen et al. 2009), similar to
previous observations with duloxetine. Duloxetine may,
therefore, exert its effects on pupillary function via both
noradrenergic and serotonergic mechanisms. Although both
duloxetine and MDMA produced mydriasis, pupil size did
not further increase after the administration of both drugs,
suggesting interactive effects of the two drugs. Moreover,
duloxetine almost completely prevented the effects of
MDMA on the light reflex. Duloxetine also markedly
inhibited the cardiostimulant, psychotropic, and neuroendo-
crine responses to MDMA in the same subjects (Hysek et al.
2012b, d; Simmler et al. 2011). Selective serotonin trans-
porter inhibitors including citalopram, fluoxetine, and
paroxetine have previously been shown to attenuate the
physiological and psychological effects of MDMA in
humans (Farre et al. 2007; Liechti et al. 2000; Liechti and
Vollenweider 2000; Tancer and Johanson 2007). Notably,
paroxetine also prevented the mydriatic effects of MDMA
(Farre et al. 2007). Together with the interactive effects of
duloxetine and MDMA in the present work, the findings
provide strong support for a role of serotonin in the mech-
anism of action of MDMA. The reduction of the effects of
MDMA on the pupil light reflex by duloxetine but not
reboxetine supports a central modulatory role of serotonin
in the effects of MDMA on pupillary function, possibly
involving central serotonergic potentiation of noradrenergic
outflow (Prow et al. 1996).
In the present study, we assessed pupillary function under
dark–light conditions, similar to other studies of the autonom-
ic effects of pharmaceuticals (Bitsios et al. 1999; Nielsen et al.
2010; Noehr-Jensen et al. 2009; Phillips et al. 2000c). The
values of the latency to the light reflex and constriction am-
plitude obtained in the present study were similar to those
measured under daylight conditions with the same pupillom-
eter (Taylor et al. 2003), indicating that these parameters may
not be critically affected by the light conditions. Overall, our
data indicate that the constriction of the pupil represents a
measure that is sensitive to pharmacological interventions and
may be relatively insensitive to changes in light conditions
compared with measures of pupil size.
In summary, MDMA increased pupil size and reduced
the response to light. The MDMA-induced prolongation of
the latency to the light reflex and reduction in light-induced
miosis indicate indirect central parasympathetic inhibition.
The faster recovery reflects increased direct sympathomi-
metic action. Both reboxetine and duloxetine interacted with
the effects of MDMA on static and dynamic measures of
pupillary function, supporting a role for both norepinephrine
and serotonin in the effects of MDMA on pupillary function.
MDMA-induced mydriasis was associated with the plasma
concentration–time curve of MDMA. The reduced miotic
response to light was highly correlated with the cardiosti-
mulant and subjective effects of MDMA and demonstrated
acute pharmacological tolerance.
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